Bioblast


Also found in: Medical.

Bi´o`blast


n.1.(Biol.) Same as Bioplast.
References in periodicals archive ?
Bioblast Pharma (ORPN) announced the sale of its Trehalose clinical development programs, including its advanced phase 2 clinical program of Trehalose to treat Oculoharyngeal Muscular Dystrophy, or OPMD, to Seelos Therapeutics (SEEL), a clinical-stage biopharmaceutical company.
Rosskamp, a pediatric endocrinologist with more than 15 years of experience in clinical medicine, is a member of the board of directors of Bioblast Pharma in Tel Aviv, Israel.
Companies Mentioned in this Report: Kissei Pharmaceutical Co., Ltd., Bioblast Pharma Ltd., Baxter International Inc., Steminent Biotherapeutics, Inc., Shenzhen Beike Biotechnology Co., Ltd., Pfizer Inc., Acorda Therapeutics, Inc., Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul, Fundacao Amparo a Pesquisa do Estado Sao Paulo, Daiichi Sankyo Company, Limited
BioBlast Pharma declared that it has named Theresa (Terri) Stevens to the newly-made designation of Chief Corporate Development Officer (CCDO).
In a controlled laboratory setting, oxygen-deficient conditions, third-party testing proved that EcoSure BioBlast fibers biodegrade at least 12 times faster than traditional polyester and petroleum-based fibers over a one-year period.
Biotechnology company BioBlast Pharma (NasdaqGM:ORPN) reported on Thursday the receipt of orphan drug designation from the European Commission for Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
BioBLAST (Better Learning through Adventure, Simulations and Telecommunication) is an "educational environment" -- built on a framework of scientific inquiry and rich content representation -- delivered on a CD-ROM.
This report provides comprehensive information on the current therapeutic developmental pipeline of Bioblast Pharma Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Biotechnology company BioBlast Pharma (NasdaqGM:ORPN) reported on Monday the launch of a Phase 3 pivotal study of Cabaletta (trehalose) in Oculopharyngeal Muscular Dystrophy (OPMD) in the US and Canada.
As compared to Alcobra, which is based on creating a single molecule, BioBlast Pharma is creating a platform of products for rare and ultra-rare genetic ailments.
Bioblast Pharma announced that it received a written notification from the listing qualifications department of the Nasdaq Capital Market notifying the company that Nasdaq has determined that Bioblast's stockholders' equity does not comply with the minimum $2.5M stockholders' equity requirement for continued listing on Nasdaq, as set forth in Nasdaq listing rule 5550.
Companies Mentioned in this Report: aTyr Pharma, Inc., Pfizer Inc., Bioblast Pharma Ltd., Santhera Pharmaceuticals Holding AG, Isis Pharmaceuticals, Inc., Genethon, AMO Pharma Limited, Alkeus Pharmaceuticals, Inc., Alfa Wassermann S.p.A, Acceleron Pharma, Inc.